GD2, PSMA and CD276 CAR-T / SZGIMI - LARVOL DELTA

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: Nov 2020 ➔ Dec 2029

Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Solid Tumor • CD276